Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29537784 | 1.00 | CYP4F2 (0.34) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL24274352 | 0.86 | CYP4F2 (0.38) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL29474176 | 0.84 | ALDH1A1 (0.41) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL29474156 | 0.83 | CYP4F2 (0.34) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL24294315 | 0.83 | CYP4F2 (0.34) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL29474191 | 0.83 | ALDH1A1 (0.38) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL29474166 | 0.82 | CYP4F2 (0.38) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL24305683 | 0.82 | CYP4F2 (0.38) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL24305684 | 0.81 | CYP4F2 (0.37) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL24294354 | 0.81 | CYP4F2 (0.37) | CYP4F2CYP4A11ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | 1ST Biotherapeutics, Inc. (KR) | 2023-09-05 | — | — | US | disclosed |
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | 1ST Biotherapeutics, Inc. (KR) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | NLRP3, NLRP1, KCNJ2 | CYP4F2 1503/4885CYP4A11 1580/4885ALDH1A1 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.